glp-1 gip lilly Lilly's Investigational Dual and Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes Eli Lilly stock soars on
Description
It is taken once a week through a subcutaneous injection (under the skin) using a pre-filled injector pen
PMID: 38017205
Dulaglutide The Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial (2019) evaluated dulaglutide (1.5 mg weekly) in 9901 T2DM patients with a broader risk profile, including 31% with prior CVD [8]
it does not tell you what to do after a missed dose
2024 June;102(6):3915
Previous work reports that the GLP-1R agonist, exendin-4, stimulates cell proliferation in juvenile but not adult human islets (73)
